[1]
“Risk of hepatitis B reactivation in rheumatic patients receiving tocilizumab treatment”, Ann Med Res , vol. 32, no. 11, pp. 512–517, Nov. 2025, Accessed: Jan. 27, 2026. [Online]. Available: http://www.annalsmedres.org/index.php/aomr/article/view/4880